Back to top
more

Kamada (KMDA)

(Real Time Quote from BATS)

$6.89 USD

6.89
30,135

+0.04 (0.58%)

Updated Aug 6, 2025 02:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Kamada (KMDA) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Kamada (KMDA) delivered earnings and revenue surprises of 55.56% and 14.20%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Equity Research

    Is Kamada (KMDA) Outperforming Other Medical Stocks This Year?

    by Zacks Equity Research

    Is (KMDA) Outperforming Other Medical Stocks This Year?

      Zacks Equity Research

      4 Undervalued MedTech Stocks to Consider Amid Volatility

      by Zacks Equity Research

      Amid turbulences of the U.S. market, some value stocks of MedTech industry appear to be lucrative investment options.

        Zacks Equity Research

        Kamada (KMDA) Gets FDA Approval for Rabies Vaccine

        by Zacks Equity Research

        Kamada Ltd. (KMDA) and partner Kedrion Biopharma and announced that FDA has approved Kedrab [rabies immune globulin (Human)] for post-exposure prophylaxis against rabies infection.

          Zacks Equity Research

          Kamada Withdraws Inhaled AAT Marketing Application in EU

          by Zacks Equity Research

          Kamada Ltd.'s (KMDA) decided to withdraw the marketing authorization application (MAA) for its inhaled formulation of Alpha-1 Antitrypsin (AAT) in the EU.

            Zacks Equity Research

            Kamada (KMDA) Posts Q1 Loss Wider than Expected, Sales Miss

            by Zacks Equity Research

            Kamada Ltd. (KMDA) reported adjusted loss of 11 cents in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 3 cents.

              Zacks Equity Research

              Puma (PBYI) Expands Study Cohort for Lead Candidate PB272

              by Zacks Equity Research

              Puma Biotechnology, Inc. (PBYI) has expanded the fourth cohort of the phase II SUMMIT study evaluating its lead candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket study).

                Zacks Equity Research

                Evoke Diabetic Gastroparesis Drug Gimoti Positive in Phase III

                by Zacks Equity Research

                Pharma, Inc. (EVOK) announced additional data from a phase III trial on Gimoti (nasal delivery), a novel formulation of its marketed drug, metoclopramide, for diabetic gastroparesis in adult women.

                  Zacks Equity Research

                  Allergan (AGN) Liletta sNDA Accepted for Review in the U.S.

                  by Zacks Equity Research

                  Allergan plc (AGN) and partner Medicines360, a nonprofit global women's health pharmaceutical company, announced that the FDA has accepted a supplemental New Drug Application (sNDA) for its marketed intrauterine system (IUS), Liletta.

                    Zacks Equity Research

                    Allergan Natrelle Inspira Breast Implants Approved in the U.S.

                    by Zacks Equity Research

                    Allergan plc (AGN) announced that the FDA has approved Natrelle Inspira SoftTouch, a new medium firmness gel, or cohesive, implant option for breast reconstruction, augmentation or revision surgery.

                      Zacks Equity Research

                      Sanofi (SNY) Closes Business Exchange Deal with Boehringer

                      by Zacks Equity Research

                      Sanofi (SNY) announced the closing of a previously announced deal to exchange its Merial animal health business with Boehringer Ingelheim's consumer healthcare (CHC) segment. The transaction was signed in Jun 2016.